Stockwinners Market Radar for May 01, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:04 EDT Cathie Wood's ARK Investment bought 169K shares of Coinbase today

19:56 EDT Impinj director buys $2.0M in common stock - In a regulatory filing, Impinj disclosed that its director Steve Sanghi bought 23.5K shares of common stock on May 1 in a total transaction size of $2.0M.

19:46 EDT Viking Therapeutics CEO sells $1.01M in common stock - In a regulatory filing, Viking Therapeutics disclosed that its CEO Brian Lian sold 45K shares of common stock on May 1st in a total transaction size of $1.01M.

19:01 EDT Dollar Tree names Mike Kindy Chief Supply Chain Officer - Dollar Tree "announced a key executive leadership addition, with Mike Kindy joining the organization as Chief Supply Chain Officer. Mr. Kindy has more than 34 years of management experience in retail logistics and operating distribution centers."

18:58 EDT Apartment Income REIT reports Q1 same-store revenue growth up 10.1%

17:42 EDT Eastern Company to close European facility - The Eastern Company announced that the Company plans to close Associated Tool Makers, its European mold tooling service facility based in the U.K. As a result, the Company expects to record charges totaling approximately $4.0M in the Q2 for severance and other related costs associated with exiting the business. "After completing a thorough review of Eastern's business and products, we determined that our mold tooling service in Europe was no longer aligned with our goal of restoring consistent, sustainable profitability. We then conducted a detailed analysis of options and decided the best course of action was to exit this business. We will continue to serve customer needs out of a U.S.-based location," said President and CEO Mark Hernandez. "We remain intently focused on executing numerous initiatives this year to improve profitability and reduce working capital."

17:33 EDT U.S. Bancorp director Wine buys 30,438 common shares - In a regulatory filing, U.S. Bancorp director Scott Wine disclosed the purchase of 30,438 common shares of the company at a price of $32.85 per share.

17:19 EDT STAG Industrial to replace Axon in S&P 400 at open on 5/4

17:18 EDT Chegg falls 33% to $11.88 after below-consensus Q2 guidance

17:16 EDT Travere Therapeutics' sparsentan study did not achieve primary efficacy - Travere Therapeutics "announced topline primary efficacy results from the pivotal Phase 3 DUPLEX Study of sparsentan, a Dual Endothelin Angiotensin Receptor Antagonist, in focal segmental glomerulosclerosis. At the end of the 108-week double-blind period, sparsentan was observed to have a 0.3 mL/min/1.73m2 per year (95% CI: -1.74, 2.41) favorable difference on eGFR total slope and a 0.9 mL/min/1.73m2 per year favorable difference on eGFR chronic slope compared to the active control irbesartan, which was not statistically significant. After 108 weeks of treatment, sparsentan achieved a mean reduction in proteinuria from baseline of 50%, compared to 32% for irbesartan. Results from the two-year analysis demonstrated that sparsentan was well-tolerated and has shown a comparable safety profile to irbesartan. The Company will engage with regulators to explore a potential path forward for a supplemental New Drug Application in the U.S. Together with its collaborator CSL Vifor, the Company also plans to engage with the European Medicines Agency to determine the potential for a subsequent variation to the Conditional Marketing Authorization of sparsentan for the treatment of FSGS, subject to a review decision on the pending application for the CMA of sparsentan in IgA nephropathy."

17:08 EDT BlackBerry to initiate review of its portfolio of businesses - BlackBerry announced that the BlackBerry Board of Directors will initiate a review of its portfolio of businesses. The assessment will assist the Board as it considers various strategic alternatives to drive enhanced shareholder value. These alternatives include, but are not limited to, the possible separation of one or more of BlackBerry's businesses. "BlackBerry is executing on a strong, well-resourced plan to deliver revenue and ARR growth, as well as significant improvements in non-GAAP EPS and cashflow this fiscal year. Although we expect achievement of this plan to deliver significant shareholder benefits, we do not believe that this is fully reflected in the market's current valuation of the Company," said John Chen, Executive Chairman & CEO. "Accordingly, the Board and management believe it is an appropriate time to initiate a comprehensive review of the company's portfolio. The review aims to identify and evaluate opportunities to further enhance shareholder value. As we undertake this review, we remain fully focused on delivering our plan and remain committed to our customers, partners and employees." The Board has not set a timetable for completing the process and does not intend to disclose developments relating to it unless, and until, the Board has approved a specific agreement or transaction or has terminated its review. There can be no assurance that the process will result in any transaction. BlackBerry will continue with the previously announced sale of substantially all of its non-core patents and patent applications to Malikie Innovations Limited, a newly formed subsidiary of Key Patent Innovations Limited. Completion of the transaction is conditional upon, among other things, satisfaction of all regulatory conditions.

17:03 EDT Soluna Holdings votes in favor of John Belizaire becoming CEO - Soluna Holdings announced the Soluna Board of Directors has voted in favor of John Belizaire becoming CEO of Soluna Holdings, in addition to his role as CEO of Soluna Computing. Belizaire is one of the founders of Soluna Computing prior to its acquisition by Mechanical Technology, and will succeed Michael Toporek as CEO of Soluna Holdings. Toporek will become Executive Chairman of the Board of Directors, succeeding William Phelan, who will become Lead Independent Director of the company. The transition is effective immediately.

16:45 EDT Harbor Custom Development files to sell common stock, warrants, no amount given

16:41 EDT Enact Holdings increases quarterly dividend 14% to 16c per share - Enact Holdings announced that its board of directors declared a quarterly dividend of 16c per common share, an increase of over 14% from the prior quarter's dividend. This quarter's dividend will be payable on June 14 to shareholders of record on May 31. All future dividends are subject to board approval.

16:40 EDT 3D Systems to acquire Wematter, terms undisclosed - 3D Systems announced that it has entered into an agreement to acquire Wematter, a Swedish 3D printer manufacturer, that will broaden 3D Systems' Selective Laser Sintering, or SLS, portfolio. Wematter designed and introduced the Wematter Gravity in 2019 which brought an affordable, turnkey SLS solution to the market. The closed-loop system is designed to operate in a smaller-footprint environment outside of a manufacturing floor, such as an office. Since that time, Wematter has expanded to three models - Gravity Essential, Gravity Essential+, and Gravity Enterprise - to facilitate the adoption of SLS for a wider range of user environments. As a result of this acquisition, 3D Systems will be able to make SLS available to a broader range of customers with a high-reliability, affordable solution for the production of end-use parts. The Wematter Gravity was designed to make additive manufacturing accessible in smaller environments. 3D Systems expects this transaction to close in July of 2023.

16:36 EDT EnerSys appoints Shannon Thomas as new CHRO - EnerSys announced the appointment of Shannon Thomas as its new Chief Human Resources Officer CHRO . She will join the executive team and report directly to EnerSys's President and CEO David M. Shaffer. In this role, Ms. Thomas will be responsible for the strategy, leadership and operations of the global Human Resources function, overseeing the company's talent lifecycle and development, total rewards, as well as its diversity, equity, and inclusion initiatives.

16:31 EDT WV American Water submits rate request with PSC of West Virginia - West Virginia American Water filed a rate adjustment request today with the Public Service Commission of West Virginia reflecting approximately $340M in water and wastewater system investments made from 2020 through February 2025 to continue providing safe and reliable service. The company continues to make needed investments to replace aging infrastructure, comply with water quality and environmental regulations and meet customers' water and wastewater service needs. If approved, new rates reflecting these investments would not go into effect until February 2024. "This rate request provides for recovery of our investment from 2020 to present and seeks to facilitate future system investments into 2025," said Robert Burton, president of West Virginia American Water. "The rates established in our last request did not recognize more than $48 million in system investments we had made by the time those rates took effect. Today's filing seeks to remedy this investment recovery delay and to create long-term rate stability for our customers by accounting for the investment occurring throughout our water and wastewater systems."

16:26 EDT MGM Resorts reports Q1 Las Vegas Strip Resorts net revenue $2.2B - Las Vegas Strip Resorts: Net revenues of $2.2 billion in the current quarter compared to $1.7 billion in the prior year quarter, an increase of 31%. The current quarter benefited from the inclusion of The Cosmopolitan, an increase in business volume as the early part of the prior year quarter was negatively affected by the spread of the omicron variant, and an increase in REVPAR, partially offset by the disposition of The Mirage; Same-store net revenues (adjusted for acquisitions and dispositions) of $1.9 billion in the current quarter compared to $1.5 billion in the prior year quarter, an increase of 22%; Adjusted Property EBITDAR of $836 million in the current quarter compared to $594 million in the prior year quarter, an increase of 41%; Same-Store Adjusted Property EBITDAR of $706 million in the current quarter compared to $561 million in the prior year quarter, an increase of 26%; and Adjusted Property EBITDAR margin of 38.4% in the current quarter compared to 35.7% in the prior year quarter, an increase of 271 basis points primarily due to an increase in rooms revenue, as discussed above.

16:22 EDT Northern Oil and Gas raises quarterly dividend 9% to 37c per share - Northern Oil and Gas announced that its Board of Directors has declared a cash dividend on the company's common stock in the amount of 37c per share, representing a 9% increase from the prior quarterly dividend. The dividend is payable on July 31, 2023, to stockholders of record as of the close of business on June 29, 2023.

16:17 EDT Curtiss-Wright signs subsea motor pump agreement with Shell subsidiary - Curtiss-Wright (CW) "announced that it has signed an agreement with Shell Exploration & Production Company, a subsidiary of Shell plc (SHEL), to manufacture, test, and provide operational support for an Electro-Submersible Pump for a Shell offshore platform in the Gulf of Mexico. The objective of this joint initiative is to demonstrate Curtiss-Wright's canned motor technology as an effective and reliable alternative to current subsea pump technologies that reduces unplanned outages and production interruptions. In addition to delivering the ESP solution, a test facility, funded as part of the agreement, will be designed and constructed by Curtiss-Wright to enable full-power testing to demonstrate the 125-foot-long, fully assembled pump's capability and performance prior to its shipment and subsea deployment."

16:17 EDT E2open sees Q1 subscription revenue $131M-$134M

16:08 EDT Rambus sees Q2 licensing billings $61M-$67M - For the second quarter of 2023, the company expects licensing billings to be between $61 million and $67 million. The company also expects royalty revenue to be between $37 million and $43 million, product revenue to be between $50 million and $56 million and contract and other revenue to be between $18 million and $24 million.

15:02 EDT Incyte says SCRATCH-AD trial meets primary endpoint - Incyte announced new data from the Phase 2 SCRATCH-AD trial evaluating the short-term clinical benefits of Opzelura cream 1.5% to control pruritus and reduce disease severity in adult patients with atopic dermatitis, the most common type of eczema. These data were featured in a poster presentation at the Revolutionizing Atopic Dermatitis Conference, held from April 29-May 1 in Washington, D.C. Results showed that patients with AD treated with Opzelura experienced a rapid and substantial improvement in itch, which was sustained and further improved through 28 days of treatment. Specifically, the study met its primary endpoint with Opzelura-treated patients experiencing a mean (SE) -3.4 (0.28) reduction in itch from baseline at Day 2 as measured by the peak pruritus numerical rating scale (PP-NRS; an 11-point scale evaluating the peak intensity of itch over the course of 24 hours). Itch reduction was observed beginning as early as 15 minutes (2.3 [0.35]) as measured by modified PP-NRS, and the change from baseline, observed at four hours after the first application of Opzelura, was 4.2 mPP-NRS [0.31]. "AD is a chronic, immune-mediated skin condition that can be difficult to manage and causes disruptive and persistent symptoms like itch that can greatly affect patients' everyday lives," said Jim Lee, M.D., Ph.D., Group Vice President, Inflammation & AutoImmunity, Incyte. "We are pleased that the SCRATCH-AD results further emphasize the rapid impact of Opzelura on itch reduction and reinforce its profile as an effective, well-tolerated topical non-steroidal treatment for AD."

14:54 EDT Jupiter Wellness Acquisition Corp trading halted, volatility trading pause

14:08 EDT UroGen Pharma presents results of new retrospective study evaluating JELMYTO - UroGen Pharma highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO, or mitomycin, for pyelocalyceal solution presented today at the American Urological Association Meeting 2023 in Chicago, IL. Upper Tract Urothelial Cancer, or UTUC, patients in this retrospective study who underwent complete endoscopic ablation followed by JELMYTO were more likely to be disease-free at first endoscopic evaluation than those who underwent chemoablation alone -- 69% vs. 40%, whereas in the Phase 3 OLYMPUS study of JELMYTO, LG-UTUC patients in the primary chemoablation setting achieved a 59% complete response rate at first endoscopic evaluation. Response at primary endoscopic evaluation was defined as no visual tumor or negative biopsy. The rate of ureteral stenosis for those in this study who underwent complete endoscopic ablation followed by JELMYTO treatment was 23%. Ureteral stenosis was defined as a condition requiring ureteral stent or nephrostomy, or that would typically warrant stent or nephrostomy. In their publication the authors noted that longer follow-up rate is needed to determine if JELMYTO after complete endoscopic ablation of UTUC will lead to durable disease-free interval. The limitations of this study include the retrospective design, lack of a control group, the lack of a centralized pathology review, and standardized clinicopathologic assessment. Other limitations include: the assumption that complete endoscopic ablation resulted in complete tumor destruction, though data from early second-look ureteroscopy after endoscopic ablation show in-field recurrences suggesting incomplete tumor ablation; follow-up was short and the interval between surveillance ureteroscopy after initial post-treatment evaluation of surveillance was not uniform amongst centers, which may lead to bias in survivorship data; and tumor size prior to endoscopic ablation was not accounted for in this study and may have biased patients with lower tumor volume to undergo complete endoscopic ablation. To further explore the full potential of JELMYTO for the treatment of patients with UTUC, investigators are in the process of enrolling the prospective and retrospective uTRACT Registry to capture data in a large-scale, standardized manner to report further on patient outcomes following JELMYTO treatment including longitudinal follow-up.

14:00 EDT FDA conditionally approves first drug for anemia in cats with CKD - The U.S. Food and Drug Administration announced it has conditionally approved Varenzin-CA1, the first drug for the control of nonregenerative anemia associated with chronic kidney disease, or CKD, in cats. The FDA granted conditional approval of Varenzin-CA1 to Elanco US Inc. Reference Link

13:36 EDT Brookline Bancorp falls almost 6% after reporting Q1 results - Shares of Brookline Bancorp are falling 5.46% or 52c per share in afternoon trading on Monday to $9.02 per share after reporting Q1 results late Friday afternoon.

12:53 EDT Tutor Perini trading resumes

12:36 EDT UroGen Pharma trading resumes

12:31 EDT UroGen Pharma trading halted, volatility trading pause

12:24 EDT Baosheng Media Group Holdings Ltd trading resumes

12:08 EDT Tutor Perini trading halted, news pending

12:04 EDT Microsoft, GoDaddy partner to enable payments over virtual meetings - GoDaddy (GDDY) and Microsoft (MSFT) announced a new partnership to help small businesses seamlessly accept payments during live Microsoft Teams meetings with customers. GoDaddy is one of three commerce providers Microsoft selected for this launch.

12:01 EDT Metropolitan Bank falls -15.2% - Metropolitan Bank is down -15.2%, or -$4.88 to $27.21.

12:00 EDT Heritage Insurance rises 9.0% - Heritage Insurance is up 9.0%, or 29c to $3.52.

12:00 EDT Universal Insurance rises 12.5% - Universal Insurance is up 12.5%, or $1.92 to $17.34.

11:06 EDT Playmaker Capital's Futbol Sites announces partnerships for women's football - Playmaker Capital announced that its owned and operated media business, Futbol Sites, has been named a media partner of Chilean women's football tournament, the National Women's Championship 2023, and streaming partner for professional football teams, Colo Colo and Universidad de Chile. Futbol Sites' Chile-based media property, Redgol, will lead the partnerships and livestream productions.

11:03 EDT BAE Systems, Eaton collaborate on electric drive solutions - BAE Systems (BAESY) is collaborating with Eaton (ETN) to develop electric vehicle technology solutions. Through a memorandum of understanding, the companies will initially offer a solution for the medium-duty commercial truck platforms market, with a Class-7 pickup and delivery demonstration vehicle in development. As part of the collaboration, BAE Systems will incorporate its power-dense electric motor and advanced silicon carbide/gallium nitride power electronics suite with Eaton's MD 4-speed EV transmission to provide a comprehensive EV system for medium-duty vehicles, such as those used for a variety of pick-up and delivery applications. Leveraging industry-leading technology, the complete solution will provide original equipment manufacturers with a durable, high performance, compact, efficient, and optimized system with flexibility to work with multiple zero-emission platforms.

10:52 EDT Alcon announces presence at ASCRS 2023 - Alcon announced its presence at the American Society of Cataract and Refractive Surgery 2023 Annual Meeting, taking place May 5-8 in San Diego. The company said: "The company is proud to have the benefits of its innovations featured in more studies than ever in its history. Alcon will showcase product updates that drive efficiencies for ophthalmologists and staff, and host events with surgeons sharing their real-world experiences." Alcon will present data including: Prospective Analysis of PanOptix Satisfaction and Higher Order Aberrations in Patients with Prior Myopic Laser Vision Correction, Presented by Dr. Brett H. Mueller II and Evaluation of Refractive Stability and Binocular Visual Acuity in a New Monofocal Hydrophobic Acrylic Intraocular Lens, Presented by Dr. Clayton Blehm.

10:33 EDT Air Products' LNG tech, equipment selected for Sempra's Port Arthur project - Air Products signed an agreement with Bechtel Energy Inc. to provide its proprietary LNG process technology, equipment and advisory services to Sempra Infrastructure's Port Arthur LNG Phase 1 project in Jefferson County, Texas. The Port Arthur LNG Phase 1 project is fully permitted and is designed to include two natural gas liquefaction trains, two liquefied natural gas storage tanks and associated facilities with a nameplate capacity of approximately 13 million tonnes per annum. Air Products' LNG equipment manufacturing facility in Port Manatee, Florida will manufacture two main cryogenic heat exchangers for its AP-C3MRTM LNG process technology. The expected commercial operation dates for Trains 1 and 2 for Port Arthur LNG are projected for 2027 and 2028. This is the third Sempra Infrastructure project for which Air Products' LNG technology was selected, the first being the three trains at the Cameron, Louisiana LNG facility that have been operating with AP-C3MR technology since 2019, and the second being the Energia Costa Azul liquefaction project in Mexico. Under the agreement, Air Products will provide engineering, design and manufacturing of the heat exchanger equipment for the liquefaction sections of two large trains, which will use Air Products' proprietary AP-C3MR propane pre-cooled mixed refrigerant liquefaction process technology. In addition, Air Products will provide engineering studies and technical advisory services for the installation and startup of each LNG train. The AP-C3MR process is used to produce more LNG than any other process in the world. This process is proven, highly reliable, flexible and has become the industry standard.

10:20 EDT Charlotte's Web expands distribution with Phillips Pet Food & Supplies - Charlotte's Web Holdings added Phillips Pet Food & Supplies as a distributor, covering more than 6,000 retailers representing more than 14,000 retail locations. Initial orders have been shipped and Phillips will distribute the full line of Charlotte's Web pet products, including topical pet products, and functionally focused CBD dog chews with synergistic ingredients to support specific health functions; Calming, Hips & Joints, and Cognition.

10:09 EDT First Republic no longer eligible for inclusion in S&P Dow Jones Indices - S&P Dow Jones Indices issued the following statement to clients: "The Federal Deposit Insurance Corporation announced that it has taken First Republic Bank (FRC) into FDIC receivership and entered into a purchase and assumption agreement with JPMorgan Chase & Co. (JPM) to assume all of the deposits and substantially all of the assets of First Republic Bank. Therefore, First Republic Bank is no longer eligible for inclusion in S&P DJ Indices. It is currently in a trading halt on NYSE. The index removal date will be announced at 5:15 pm through the normal channels. For index purposes, if a stock is not trading on its primary exchange or the OTC market prior to its removal date, its price will be frozen at the last traded price on the primary exchange. The removal price will depend on the stock's trading status. If it is trading on its primary exchange on the removal date, then the primary exchange closing price will be used. If it is not trading on its primary exchange but is trading on the OTC market at 4pm on the removal date, then the 4pm OTC price will be used. If it is not trading on either its primary exchange or the OTC market, then the removal price will be zero."

10:07 EDT Southwest says SWAPA's authorization vote will not affect company's operation - In a statement, Southwest said that "as they announced earlier this year, the union representing Southwest's Pilots has called for an authorization vote as a contract negotiating tactic, one that has been used by several airline unions within the last twelve months. The call for a vote is not an indication of a pending work stoppage or a disruption to Southwest's scheduled service. The Southwest Team is committed to delivering a safe and reliable travel experience to Customers." "SWAPA's authorization vote will not affect Southwest's operation or our ability to take care of our Customers," said Adam Carlisle, Vice President Labor Relations at Southwest Airlines. "Our negotiations continue, with talks resuming this week, and we'll keep working with the assistance of the National Mediation Board to reach an agreement that rewards our Pilots and places them competitively in the industry." The company also noted that it has assigned mediators from the National Mediation Board overseeing Pilot negotiations. Reference Link

10:04 EDT Mondelez opens Global Research & Development Innovation Center in NJ - Mondelez International celebrated the grand opening of its new Global Research & Development Innovation Center in Whippany, New Jersey. The state-of-the-art facility, which is supported by an investment of nearly $50M, includes pilot and scale-up capability for cookies, crackers and candy and supports Mondelez International as an innovative global snacking leader. The Innovation Center provides new capabilities and technologies that propel R&D for consumer-loved snacks, including OREO cookies, Ritz crackers and Sour Patch Kids candies. With the addition of the Whippany, NJ Global Innovation Center, Mondelez further expands its footprint in New Jersey, at a location close in proximity to the company's North American headquarters office. More than 50 talented R&D makers and bakers who support the Mondelez business in North America and around the world will work at the new Global Innovation Center, from which they will partner closely with teams in North America, as well as teams across Mondelez businesses and R&D facilities around the globe. Among the many innovations planned, the Whippany team will play an important role in supporting innovation on electric baking technology which supports the company's 2050 goal of net zero carbon emissions across its value chain.

10:00 EDT PNC Financial falls -5.6% - PNC Financial is down -5.6%, or -$7.29 to $122.96.

10:00 EDT AMTD Digital falls -17.6% - AMTD Digital is down -17.6%, or -$1.48 to $6.92.

10:00 EDT Corporacion America Airport rises 8.9% - Corporacion America Airport is up 8.9%, or 95c to $11.64.

09:47 EDT PNC Financial falls -5.0% - PNC Financial is down -5.0%, or -$6.48 to $123.77.

09:47 EDT AMTD Digital falls -14.0% - AMTD Digital is down -14.0%, or -$1.18 to $7.22.

09:47 EDT Manitowoc rises 8.8% - Manitowoc is up 8.8%, or $1.34 to $16.63.

09:43 EDT Conformis receives FDA approval for Identity Imprint CR KRS with CS insert - Conformis has received FDA approval for its Identity Imprint Cruciate Retaining Knee Replacement System with Cruciate Sacrificing Insert, the FDA said on its website. Reference Link

09:37 EDT TOP Financial Group Ltd trading resumes

09:36 EDT Lordstown sinks 17% to 44c after Foxconn asserts agreement breach

09:35 EDT Foxconn says Lordstown Motors in breach of investment agreement - Lordstown Motors disclosed that on April 21, it received a letter from Foxconn asserting that the company was in breach of the investment agreement due to its previously disclosed receipt of a notice from the Nasdaq indicating the company was no longer in compliance with the $1.00 minimum bid price requirement for continued listing. Foxconn purported to terminate the investment agreement if the breach is not cured within 30 days. Foxconn has notified Foxconn that it believes the breach allegations in the notice are without merit. The investment agreement, by its terms, does not permit Foxconn to terminate it following the initial closing, and in any event, Foxconn cannot exercise termination rights because Foxconn has breached the investment agreement by failing to use necessary efforts to agree upon the electric vehicle program budget and EV program milestones to facilitate the funding of the additional preferred stock investment, Foxconn said in a filing. Therefore, the company believes the investment agreement remains in effect and intends to enforce its rights thereunder. Lordstown said it is in discussions with Foxconn to seek a resolution regarding these matters. However, to date, Foxconn has declined to revoke its "invalid" termination notice and has failed to confirm that it will proceed with the subsequent common closing or any preferred stock closing, it added. If the closing and funding do not occur, the Lordstown said it "will be deprived of critical funding necessary for its operations." The company is evaluating its legal and financial alternatives in the event a resolution is not reached. It added, "IF we are unable to resolve our dispute with Foxconn in a timely manner on terms that allow us to continue operating as planned, identify other sources of funding, identify a strategic partner and resolve our significant contingent liabilities, we may need to curtail or cease operations and seek protection by filing a voluntary petition for relief under the Bankruptcy Code. If this were to occur, the value available to our various stakeholders, including our creditors and stockholders, is uncertain."

09:33 EDT Tivic Health appoints Kimberly Bambach as interim CFO - Tivic Health Systems announced the appointment of veteran Kimberly Bambach to serve as Interim CFO of the company and the engagement of Christina Valauri as a strategic advisor to the Board of Directors. Bambach most recently served as CFO of Jushi Holdings Inc., where she played a pivotal role in the company's rapid growth driving over a dozen acquisitions in a complex regulatory environment. Valauri will serve as a strategic advisor to Tivic's board of directors. Ms. Valauri is the founding partner and CEO of Sagestone Advisory, LLC and a partner of NextGen Venture Partners, an early stage venture capital firm with a network of 1600 proven entrepreneurs and accomplished professionals.

09:32 EDT TOP Financial Group Ltd trading halted, volatility trading pause

09:19 EDT Yield10, Marathon Petroleum sign LOI for potential investment, offtake agreement - Yield10 Bioscience (YTEN) has signed a non-binding Letter of Intent with Marathon Petroleum (MPC) for a potential investment and offtake agreement for low-carbon intensity Camelina feedstock oil for use in renewable fuels production. Marathon is a leading, integrated downstream energy company in the U.S. In connection with the execution of the LOI, the Company also sold and issued a senior unsecured convertible promissory note to an affiliate of Marathon in the original principal amount of $1M, which is convertible into shares of the Company's common stock or other Qualified Securities, subject to certain conditions and limitations set forth in the Convertible Note. The Company plans to use the net proceeds from the Convertible Note for working capital and general corporate purposes. Additional information regarding the Convertible Note will be included in a Form 8-K to be filed by the Company with the Securities and Exchange Commission.

09:16 EDT Edible Garden ships spring ornamentals grown in Heartland facility - Edible Garden has begun shipping spring ornamentals, grown in its Edible Garden Heartland facility in Grand Rapids, Michigan. The lineup of spring ornamentals includes various-sized hanging baskets of petunias, geraniums, impatiens, begonias, dahlias, and other accent plants.

09:13 EDT BitNile.com announces beta launch of social gaming on metaverse platform - BitNile Metaverse announced the Beta launch of Roulette with the public release expected this week. Roulette is the first of many social games expected to be released on the Platform that offer real-world money prizes through a sweepstakes model. Sweepstakes are only open to residents of the United States who are at least eighteen years old or the age of majority in their jurisdiction at the time of entry. Participation is void where prohibited by law. BitNile Metaverse, through its wholly owned subsidiary BitNile.com, owns and operates the Platform.

09:12 EDT California Resources names Manuela Molina CFO - California Resources announced that Manuela Molina has been appointed as executive VP and CFO, effective May 8. As previously announced, CRC's prior CFO Francisco Leon was named president and CEO and a member of the company's board of directors as of April 28. Molina is an energy executive with more than 25 years of corporate finance, capital markets and project financing experience and brings an extensive background in the development of energy infrastructure projects in the natural gas and power sectors. She joins CRC from Sempra Energy (SRE).

09:05 EDT Plug Power unveils new high-power stationary fuel cell system - Plug Power unveiled a new high-power stationary fuel cell system for charging commercial electric vehicle, EV, fleets. Plug provides operators with a new solution: a clean hydrogen-powered fuel cell system that cost effectively charges EV fleets, getting zero-emission EV vehicles deployed to meet fleet operator's sustainability and operational goals. "As EV adoption increases dramatically over the next few years and electricity demand strains the grid, our new high-power fuel cell system will be a game changer for the EV industry," said Jose Luis Crespo, General Manager of Applications and Global Accounts for Plug. "Customers are approaching Plug for hydrogen power generation options, and we expect this offering to be one of the largest applications for stationary use this year."

09:04 EDT CN announces Unifor ratifies collective agreements - CN announced that Unifor has ratified its collective agreements with the Company. The collective agreements cover approximately 3,000 CN employees working in various departments such as Mechanical, Intermodal, Facility Management, and in clerical positions in Canada.

09:03 EDT Sarcos Technology, VideoRay enter pact to integrate underwater robotic systems - Sarcos Technology and VideoRay, a manufacturer of underwater robotic systems, announced that the companies have signed an agreement to offer integrated underwater robotic systems combining VideoRay remotely operated vehicles, or ROVs, with the Sarcos Guardian Sea Class robotic system including its power-efficient dexterous arms. Under the terms of the agreement, Sarcos and VideoRay will each be able to sell an integrated underwater robotic system, as well as their respective individual products, and provide replacement parts and repair services and support.

09:02 EDT Crypto Company's Blockchain Training Alliance signs new engagement - The Crypto Company announced that its 100% owned subsidiary, Blockchain Training Alliance, has signed a new engagement with one of the top accounting firms in the world.

09:01 EDT MGM Resorts to acquire majority of Push Gaming, terms not disclosed - MGM Resorts International announced its wholly owned subsidiary, LeoVegas, has entered into an agreement to acquire the majority of game developer Push Gaming Holding Limited and its subsidiaries, and the future operating commitment of the founding management team. Push Gaming is an innovative creator of highly entertaining digital games for betting and gaming companies. The company is a proprietary content provider that offers more than 30 games, such as Razor Shark, Wild Swarm, Big Bamboo, and Jammin' Jars to over 200 operators globally. As part of LeoVegas, Push Gaming will remain under the same management team and its 100+ employees will continue to develop high-quality games, distributed via their own platform and remote gaming server. The transaction is subject to regulatory and customary approvals and is expected to be completed in the third quarter of 2023.

09:00 EDT Midwest Holding Inc trading resumes

08:49 EDT Nano-X Imaging announces FDA clearance of Nanox.ARC Imaging System - NANO-X IMAGING announced that it has received a 510(k) clearance from the U.S. Food and Drug Administration to market the multi-source Nanox.ARC, including the Nanox.CLOUD, its accompanying cloud-based infrastructure. Nanox.ARC is a stationary X-ray system intended to produce tomographic images of the human musculoskeletal system adjunctive to conventional radiography on adult patients. Representing a major advancement in X-ray technology, Nanox.ARC is a multi-source digital 3D tomosynthesis system that utilizes novel, cold cathode X-ray tubes, which the Company intends to offer using an innovative pay-per-scan business model. The FDA cleared Nanox.ARC for use in professional healthcare facilities or radiological environments, such as hospitals, clinics, imaging centers, and other medical practices by trained radiographers, radiologists, and physicians, and has the potential to increase availability to medical imaging around the world, once approved by local regulatory authorities and deployed at scale.

08:41 EDT SKYX Platforms closes acquisition of Belami e-commerce - SKYX Platforms has closed the strategic acquisition of Belami e-commerce, an established lighting and home decor company with 64 websites, $88 million in revenues and $4.3 million in EBITDA in 2022.The acquisition of the strategic e-commerce lighting and home decor conglomerate will serve as a growth, marketing and educational platform for the significant lifesaving, cost saving, time saving and simplicity aspects of SKYX's platform technologies. This will provide new distribution channels to the retail and professional segments - including builders, architects and home designers. A majority of the purchase price of the acquisition was paid with the Company's common stock, reflecting an acquisition price of 6 times EBITDA, totaling approximately $26 million for 100% ownership. The cash portion for the closing was financed by major leading shareholders of SKYX. Owners and management of Belami, who are now SKYX shareholders, will remain with the Company after the acquisition to continue to run the successful business and integrate SKYX plug and play ceiling technologies into its product mix.

08:40 EDT Jabil CEO Kenny Wilson officially assumes role - Jabil announced that Kenny Wilson has officially assumed the role of CEO. Wilson, a long-time leader within Jabil, succeeds Mark Mondello who will remain with the company as executive chairman of the board. Wilson was also appointed to the board of directors last week.

08:39 EDT Planet Fitness announces return of its High School Summer Pass program - Planet Fitness announces the return of its High School Summer Pass program, inviting high schoolers ages 14 - 191 to work out for free at any of its more than 2,400 Planet Fitness locations throughout the United States and Canada from May 15 through August 31. Starting today, high schoolers can visit PlanetFitness.ca/SummerPass to register for the program before gaining club access starting Monday, May 15. Teens under 18 in the U.S. and under 19 in Canada must register with a parent or guardian online or in-club.

08:37 EDT Evoke Pharma announces new GIMOTI patent listed in FDA Orange Book - Evoke Pharma announced that its recently issued U.S. patent related to GIMOTI, No. 11,628,150 is now listed in the U.S. Food and Drug Administration, FDA, publication, "Approved Drug Products with Therapeutic Equivalence Evaluations", commonly known as the "Orange Book". The patent titled "Nasal Formulations of Metoclopramide" covers a collection of nasal solutions of metoclopramide and its characteristics when formulated. This new patent is now listed in the FDA's Orange Book and carries a patent term to 2029. The listing of the patent in the Orange Book adds additional patent protection for GIMOTI beyond the prior two listed patents. "We are thrilled to be awarded another significant win on the intellectual property front through the listing of our recently granted GIMOTI patent, which will now be our third entry into the FDA's Orange Book," commented David Gonyer, Chief Executive Officer of Evoke Pharma. "This update adds to the list of confirmations from the USPTO regarding our patent estate and continues to affirm the novelty of GIMOTI. We remain committed to pursuing all measures to ensure the long-term availability of GIMOTI to patients who need this evidently important medication."

08:36 EDT Biomea says FDA clearance of IND application to begin Phase I trial of BMF-500 - Biomea Fusion announced that the U.S. Food and Drug Administration, FDA, has cleared the company's Investigational New Drug, IND, application to begin a Phase I trial, COVALENT-103, of BMF-500, an investigational covalent FLT3 inhibitor, in adult patients with relapsed or refractory acute leukemia. "BMF-500 is an exceptionally potent molecule and the second covalent inhibitor we have developed in-house and advanced to the clinic showing high target selectivity and inhibition. We are planning single agent studies of BMF-500 as well as combination studies with BMF-219 to explore the potential of this powerful dual-mechanistic approach to amplify and sustain patient treatment responses," said Thomas Butler, Biomea's CEO and Chairman of the Board. "I would like to thank the FDA, our contract research organizations partners, our consultants, our investors, and of course TEAM FUSION for the commitment, guidance, support, and tireless effort in getting BMF-500 from bench to the clinic. It has been a true community effort, and we are humbled by the opportunity to potentially help patients fight and win against these aggressive cancers."

08:35 EDT Newtek Bank increases client deposits by 121% since December 31, 2022 - NewtekOne announced that its subsidiary Newtek Bank N.A. had an 121% increase in its client deposits to approximately $310 million year to date through April 28, 2023, compared to $140 million in client deposits at December 31, 2022. The Company acquired the National Bank of New York City, and renamed it Newtek Bank, N.A., on January 6, 2023. The amount of uninsured client deposits was approximately 5.5% as of March 31, 2023. Barry Sloane, President, Chairman and CEO commented, "We are very pleased to be able to report such a strong increase in client deposits since December 31, 2022. Following the acquisition, Newtek Bank rolled out its digital account-opening solution, which is part of the Apiture Digital Banking Platform, one of Newtek Bank's technology solutions providers. After making some adjustments to the Apiture DAO solution, Newtek Bank began to aggressively promote digital account opening and its online banking platform beginning in March. From March 2023 through April 28, 2023, of the $170 million increase in client deposits, in excess of $115 million emanated from the digital platform. We are incredibly appreciative of the efforts by Apiture, making Newtek Bank a true technology-enabled bank. In addition, in April 2023, Newtek Bank began funding the SBA 7(a) loan origination pipeline transferred from Newtek Small Business Finance, the Company's non-bank SBA 7(a) lender. As we announced on Friday of last week, Newtek Bank has also been granted PLP status, and will be able to originate SBA 7(a) loans under PLP-delegated authority without having to go to the SBA for approvals. This delegated authority is an honor granted only to the most experienced SBA loan originators and underwriters. NSBF will remain a non-bank subsidiary of the Company while NSBF continues to service and wind-down its legacy SBA 7(a) loan portfolio in securitization structures. Furthermore, Newtek Bank intends to utilize its client deposits to fund SBA 7(a) loans, SBA 504 loans, conforming commercial and industrial loans, and conforming investor-based commercial real estate loans."

08:33 EDT Acer Therapeutics announces update on OLPRUVA commercial launch - Acer Therapeutics announced an update on progress in support of its commercial launch of OLPRUVA for oral suspension, including drug availability now expected earlier than anticipated in mid-June 2023, subject to additional capital. "Since the U.S. FDA approval of OLPRUVA(TM) at the end of 2022, we and our partners have been working diligently to bring this innovative treatment option to UCD patients in need as soon as possible," said Chris Schelling, CEO and Founder of Acer. "As a result of these efforts, I am pleased to report we are ahead of our anticipated launch schedule and now expect drug availability beginning in mid-June 2023. We have also made significant progress in our ongoing discussions with payers regarding reimbursement, increased physician awareness and interest, and built out our patient support and fulfillment program. We look forward to continued progress across these and other launch initiatives and to delivering OLPRUVA to patients starting in mid-June 2023, subject to additional capital."

08:32 EDT Winnebago completes acquisition of Lithionics Battery - Winnebago Industries has completed its previously communicated acquisition of Lithionics Battery, a premier lithium-ion battery solutions provider to the recreational equipment and specialty vehicle markets.

08:31 EDT ePlus acquires CCI Systems' Network Solutions Group - ePlus has acquired certain assets of the Network Solutions Group, a business unit of CCI Systems. NSG is a Michigan-based provider of networking services and solutions focused in the broadband Service Provider end-market. The acquisition of certain assets and liabilities of CCI Systems, Inc. closed on April 30, 2023. Terms of the transaction were not disclosed and are not expected to have a material impact on ePlus' FY24 results.

08:29 EDT DSS announces distribution date of Sharing Services shares - DSS announced the distribution date for the common stock of Sharing Services Global Corporation that is beneficially held by DSS, directly and through its subsidiary, Decentralized Sharing Systems. As previously announced, DSS Inc., together with its subsidiary DSSI, distributed approximately 280 million shares of Sharing Services' common stock beneficially held by DSS and DSSI in a distribution to holders of DSS common stock, par value $0.02 per share as of April 28, 2023. Each share of DSS Common Stock outstanding as of 5:00 p.m., New York City time, held on April 28, 2023, will entitle the holder thereof to receive two SHRG common stock shares to be distributed on May 4, 2023. Sharing Services is a diversified direct marketing company that is currently listed on the OTCQB Market and is in the process of up-listing to Nasdaq. Upon completion of the Distribution, DSS and its subsidiary, DSSI, will retain an ownership interest of approximately 7% in Sharing Services Global Corporation.

08:27 EDT enVVeno Medical expects cash to fund operations through end of 2024 - The Company ended the quarter with $34.2 million in cash and investments. Based on management's current expectations, the Company believes it has sufficient cash to sustain operations through the end of 2024.

08:24 EDT Ortho Dermatologics announces FDA acceptance of NDA filing for IDP-126 Gel - Bausch Health Companies announced that the U.S. Food and Drug Administration has accepted the New Drug Application for investigational IDP-126 Gel with a Prescription Drug User Fee Act action date of October 20, 2023. If approved, IDP-126 has the potential to be the first of its kind fixed dose triple combination treatment for acne vulgaris. The NDA submitted for IDP-126 includes data from two successfully completed Phase 3 multicenter, randomized, placebo controlled clinical trials in 363 patients with acne vulgaris. Both studies met all co-primary efficacy endpoints, including absolute change from baseline in inflammatory lesion count, absolute change from baseline in non-inflammatory lesion count and percentage of patients achieving treatment success. Both studies showed treatment-emergent adverse events were of mild to moderate severity.

08:23 EDT Proxy firms recommend TravelCenters shareholders vote for BP deal - TravelCenters of America announced that leading independent proxy advisory firms Institutional Shareholder Services or ISS and Glass Lewis & Co. have recommended that TA shareholders vote "for" the previously announced all-cash acquisition of TA by BP Products North America in advance of TA's upcoming Special Meeting of Shareholders scheduled for May 10, 2023. As previously announced, under the terms of the pending transaction, BP will acquire all of the outstanding shares of TA common stock for $86 per share in cash. TA shareholders of record as of the close of business on March 23 are eligible to vote on the pending transaction and are encouraged to do so as soon as possible. Subject to shareholder approval, the transaction is expected to close on May 15. The $86 transaction price represents an 84% premium to TA's average trading price of $46.68 over the 30 days ended February 15 the date the BP merger agreement was signed. The total equity value of the transaction is approximately $1.3B.

08:21 EDT Capital Power chief strategy, sustainability officer Kate Chisholm retires - The company said, "On April 13, 2023, the Company announced internally that Kate Chisholm, our Senior Vice President and Chief Strategy and Sustainability Officer has advised of her intention to retire effective July 4, 2023. Kate has been an integral part of the Executive Team with outstanding service and valuable contributions since the inception of Capital Power. Announcement for Kate's replacement will occur in due course."

08:20 EDT Capital Power appoints Avik Dey as president, CEO - On April 19, 2023, the Company's Board of Directors announced that it unanimously selected Avik Dey to be its next President and Chief Executive Officer and become a member of the Board of Directors, effective May 8, 2023. The appointment follows the planned retirement of Brian Vaasjo who will support Mr. Dey in an advisory role for six months to ensure a seamless transition.

08:19 EDT Actelis Networks showcases new hybrid fiber-copper solutions - Actelis Networks announced the introduction of next generation hybrid fiber-copper solutions designed to enable rapid deployment of cyber-safe, gigabit connectivity to locations where fiber installation is difficult and costly. The newly introduced solutions support a variety of IoT applications for rail, military and campus networks, 5G/mobile base stations as well as residential and commercial broadband, including Multiple Dwelling Units such as apartments and condos. The introduction follows successful tests with rail and military customers that exceeded expectations. "Our new line of gigabit hybrid fiber-copper products is very unique in that it utilizes existing wiring but is able to transmit multi-gig, fiber-grade connectivity over long distances, which provides tremendous cost and time savings for network operators," said Tuvia Barlev, Chairman and CEO of Actelis. "The flexibility of the solution allows for an almost unlimited number of applications, from rail networks to enabling high-speed internet for unserved and underserved communities."

08:17 EDT TFI International announces two less-than-truckload acquisitions - TFI International announced it has agreed to acquire Siemens Transportation Group, STG, and has completed the acquisition of Hot Line Freight Systems. Terms of the transactions were not disclosed. "We are pleased to be expanding our LTL footprint in both Canada and the US with these two LTL acquisitions," said Alain Bedard, Chairman, President, and Chief Executive Officer of TFI International. "STG's impressive family-run approach has attracted a loyal customer base across diverse industries, and its compelling geographic presence and well-maintained equipment strategically complement our growing network. Hot Line is another highly attractive acquisition with well-run operations and a strong presence in the midwestern US that will further bolster our LTL presence while allowing us to ramp its cross-border business. We are thrilled to welcome Doug, Paul and their impressive teams to our growing family of companies and look forward to watching both STG and Hot Line succeed under the TFI International umbrella."

08:15 EDT Ryvyl engages Kingswood Capital Partners as placement agent for spin-off - RYVYL announced the engagement of Kingswood, a division of Kingswood Capital Partners as its placement agent and advisor in connection with the planned spin-off of coyni, a wholly owned subsidiary of RYVYL, and subsequent public offering. The planned offering of approximately $40 million with a NASDAQ uplisting is based on an estimated valuation of $200 million for Coyni's assets and merging of other revenue sources. The Company has not obtained an independent third-party valuation of coyni. The Company is evaluating additional details regarding the spin-off and offering and will provide further information when available. RYVYL also completed the acquisition of 97.7% ownership in Logicquest, a shell company, for the purchase price of $225,000. The Company intends to transfer the assets of coyni to Logicquest and subsequently spin-off Logicquest. Upon completion of the spin-off and public offering, RYVYL intends to pay a special equity dividend to shareholders. There can be no assurance as to the timing or whether the Company will be able to consummate the spin-off of Logicquest.

08:14 EDT FuelCell receives order from ExxonMobil for long-lead fuel cell stack module - FuelCell Energy (FCEL) has received an order from ExxonMobil for long-lead fuel cell stack module equipment and engineering support required to implement a potential demonstration of modular point source carbon capture at an ExxonMobil facility. While ExxonMobil has not yet made a final investment decision, this order advances critical-path equipment procurement and module engineering work. The commercial demonstration project is anticipated to be a full scale prototype of the modules used in large-scale systems for industrial and commercial point source carbon capture applications. "FuelCell Energy continues to gain confidence in achieving large scale commercialization of FuelCell Energy's carbonate technology for industrial and commercial point source carbon capture. We believe that this technology will address one of the largest environmental challenges of today, CO2 emissions from industrial and commercial exhaust streams and power generation," said Jason Few, President and Chief Executive Officer of FuelCell Energy. "We see market demand across various commercial and industrial segments to scale and commercialize our unique carbon capture solution, which captures carbon dioxide from various exhaust streams, while generating additional power and hydrogen. We believe our carbon capture solution is the only solution that can capture carbon while producing electricity and hydrogen at the same time. Traditional amine solutions penalize power output by 20-35% of total power production," added Few.

08:13 EDT Immutep receives approval to initiate INSIGHT-005 trial - Immutep Limited announces it has received regulatory approval from the Paul-Ehrlich-Institut, German Federal Institute for Vaccines and Biomedicines, to initiate INSIGHT-005, an investigator-initiated, open-label Phase I trial evaluating the safety and efficacy of eftilagimod alpha in combination with BAVENCIO in up to 30 patients with metastatic urothelial carcinoma. "We are excited to get this important trial underway. In addition to possibly bringing a new chemo-free treatment option to patients with advanced urothelial cancer, we hope to further build upon the encouraging clinical data we have seen to date combining efti and avelumab in other challenging cancers. Efti's unique activation of antigen-presenting cells to fight cancer has shown a benefit with avelumab, and we believe this dual IO-IO approach has broad potential to drive superior clinical outcomes across a variety of indications, including bladder cancer where avelumab monotherapy has regulatory approval," said Immutep CEO, Marc Voigt.

08:13 EDT Kiromic BioPharma announces FDA authorization of Deltacel IND application - Kiromic BioPharma announced that the FDA has authorized the company's investigational new drug, or IND, application to initiate a Phase 1 clinical trial to evaluate Deltacel for patients with non-small cell lung cancer, or NSCLC.

08:10 EDT Proterra announces appointment of David Black as CFO - Proterra (PTRA) announced the appointment of David Black, a public company finance executive with more than 30 years' experience in public corporate accounting and finance leadership, as the Company's new Chief Financial Officer, CFO, effective May 16, 2023. Karina Padilla, the Company's current CFO, will step down from her role effective May 15, 2023. Padilla will remain with the Company as a non-executive officer employee through June 2, 2023 and will work closely with Black to support a smooth transition of responsibilities. Prior to joining the Company, Black served as a Special Advisor to the CEO of BWX Technologies (BWXT).

08:09 EDT Erasca announces U.S. FDA granted FTD to ERAS-801 - Erasca announced the United States Food and Drug Administration, FDA, has granted Fast Track Designation, FTD, to ERAS-801 for the treatment of adult patients with glioblastoma with epidermal growth factor receptor gene alterations. ERAS-801 is an orally bioavailable, small molecule EGFR inhibitor that exhibited substantial central nervous system penetration in animal studies. "Receiving FTD from the FDA underscores the serious unmet medical need in patients with GBM and reinforces the promise that ERAS-801 may offer as a differentiated treatment option," said Jonathan E. Lim, M.D., Erasca's chairman, CEO, and co-founder. "GBM is an aggressive malignancy with high rates of relapse and a five-year survival rate below 10%. While over half of GBM cases are driven by EGFR alterations and/or amplifications, there are no approved EGFR inhibitors for the treatment of GBM due to the lack of sufficient brain penetration to treat primary brain tumors as well as lack of activity against EGFR alterations observed in GBM, such as EGFRvIII. To help overcome these limitations, ERAS-801 was specifically designed to have high CNS penetration and broad activity against both oncogenic and wildtype EGFR. We look forward to working closely with the FDA to expedite clinical development of ERAS-801 for these patients and anticipate reporting initial monotherapy data from the Phase 1 THUNDERBBOLT-1 trial in recurrent GBM (rGBM) in the second half of 2023."

08:07 EDT Nexstar reaches multi-year distribution agreement with Hulu - Nexstar announced that it has reached a comprehensive multi-year distribution agreement with Hulu. The deal covers 122 of the company's local television stations, including the launch of the company's MyNetworkTV affiliates and independent stations, and the continued carriage of its cable news network, NewsNation, on Hulu + Live TV. Financial terms of the agreement were not released.

08:07 EDT OrthoPediatrics continues sponsorship of 2023 POSNA annual meeting - OrthoPediatrics announced its continued support of the 2023 Pediatric Orthopaedic Society of North America annual meeting this week in Nashville, Tennessee. At the Annual Meeting the Company highlighted its growing portfolio of pediatric-specific solutions at its exhibit booth. The Company sponsored a sub-specialty session focused on hip dysplasia in pediatric patients. This session covered two extreme and regularly occurring situations, including stable dysplasia in infants as well as severe dysplasia and degeneration in adolescents. Additionally, the Company highlighted progress with the ApiFix non-fusion technology, hosting a workshop for current users of the system to share their experiences and best-practice, as well as discuss positive one-year ApiFix follow-up clinical data from 54 patients in the registry who are over one-year post surgery. OrthoPediatrics has established a longer-term commitment to POSNA deepening its commitment to providing ongoing support of specialty symposiums and awarding educational grants and scholarships to attendees. The Company has elevated its sponsorship level and is now the only Emerald Sponsor of the organization.

08:05 EDT ADDvantage appoints Brian Davidson as CRO - ADDvantage Technologies Group announced that Brian Davidson has joined the Company as its new Chief Revenue Officer, effective May 1, 2023. Davidson joins ADDvantage Technologies from OneVizion, an international software provider for the deployment of critical infrastructure to the utility and telecom industries, where he served as CRO. In this role, he spearheaded strategy, marketing, and new account acquisition, including playing a significant role in securing numerous tier-one national accounts

08:04 EDT Ardelyx announces additional data supporting first-in-class IBSRELA - Ardelyx announced that additional data supporting the efficacy and safety of IBSRELA will be presented in a poster at the 2023 Digestive Disease Week Conference, DDW 2023, to be held May 6-9, 2023, in Chicago, Illinois. Title: "Analysis of Patient-Reported Treatment Satisfaction and Abdominal Pain Score in Patients with Irritable Bowel Syndrome with Constipation, IBS-C, Treated with Tenapanor." In addition to the poster presentation during DDW, Ardelyx is sponsoring a Product Theater titled: Discover a Different Mechanism of Action to Treat Adults with IBS-C: A Case Based Discussion, on May 8, 2023 where Darren Brenner, M.D., Professor of Medicine and Surgery, Northwestern University Feinberg School of Medicine, will review the multifactorial pathophysiology of IBS-C, the novel mechanism of action of IBSRELA, and efficacy and safety data of IBSRELA from the Phase 3 clinical trial program. Dr. Brenner will also review two patient cases and discuss treatment decisions in IBS-C.

08:03 EDT AutoNation appoints Richard Lennox as new CMO - AutoNation announced Richard Lennox as its new Chief Marketing Officer, effective May 15. Lennox most recently served as Chief Customer & Brand Officer at Macy's. Prior to Macy's, Lennox served as Chief Marketing Officer at Toys R Us and Zales. Marc Cannon will transition into a new role focused on corporate responsibility, encompassing AutoNation's DRVPNK activities, and will retire at the end of the year.

07:50 EDT Micromobility.com achieves compliance with Nasdaq minimum bid rule - Micromobility.com announces that it has achieved compliance with the Nasdaq Capital Market's minimum bid price requirement. On April 30, micromobility.com received a letter from the Listing Qualifications Department of the Nasdaq Stock Market, confirming that it has met the required threshold, as stipulated by the Hearing Panel's amended decision of March 7 . The Company attained compliance when the closing bid price for its common stock remained at or above the required threshold for twenty consecutive business days, successfully resolving the matter. Micromobility.com Inc. remains deeply committed to maintaining its listing on the Nasdaq Capital Market and expresses gratitude for the unwavering support of its shareholders, customers, and partners. The Company will continue to innovate, expand its offerings, and drive growth within the micro-mobility sector, striving to provide exceptional value and service to all stakeholders.

07:46 EDT Cardlytics announces update to Bridg earnout payments - Cardlytics announced a determination of the First Anniversary Payment Amount in relation to the acquisition of Bridg. The First Anniversary Payment Amount had been disputed by the parties, and pursuant to the dispute resolution provision of the merger agreement, an Independent Accountant determined the First Anniversary ARR to be $23.2 million. Based on the Independent Accountant's determination and the terms of the merger agreement, the First Anniversary Payment Amount would be $208.1 million, inclusive of fees and transaction bonuses and accounting for all true-ups and credits. If Cardlytics elected to pay 70% of the consideration in common stock at the closing price as of April 28, 2023, given the favorable VWAP of $40.15, the total value of the First Anniversary Payment Amount would be $94.5 million. In sum, the total cash anticipated for both earnouts, inclusive of brokerage fees and transaction bonuses and accounting for all true-ups and credits, is $72.6 million. Cardlytics anticipates the remaining consideration for both earnouts will be paid with 3.4 million shares of Cardlytics common stock, which significantly decreases investor dilution as compared to Cardlytics' previous publicly disclosed estimates.

07:43 EDT Shyft Group to highlight market-ready blue ARC EV Delivery Vans at ACT Expo - The Shyft Group will exhibit its Blue Arc EV delivery vehicles at the 12th annual ACT Expo, taking place May 1-4 at the Anaheim Convention Center in Southern California. Attendees can visit Blue Arc EV at booth #6321 to see the all-electric Class 3 delivery vehicle designed for high-frequency, last-mile fleets and talk to engineering experts. The first order of 2,000 Blue Arc EVs goes into production in the second half of this year. Since first announcing intentions in June 2021 to bring electric vehicles to market, Shyft has successfully balanced a rapid development timeline with the robust engineering needed for hard-working commercial vehicles. The Blue Arc EV ecosystem includes Class 3, 4, and 5 all-electric walk-in vans as well as the newest introduction, a Class 5 all-electric Crew Cab. "We've met all our development milestones, and even more impressive is the quality and performance we're achieving with Blue Arc EVs," said Daryl Adams, President and CEO, The Shyft Group. "We know last-mile delivery after 50 years in this space and understand the day-to-day requirements and challenges. Our testing beyond industry requirements is based on this real-world knowledge and will allow us to provide high-performing electric delivery vehicles to our customers."

07:41 EDT Above Food to become public through Bite Acquisition business combination - Above Food and Bite Acquisition (BITE) announced that they have entered into a definitive business combination agreement, which values the company at a pro forma enterprise value of approximately $319M. Upon closing of the proposed transaction, Above Food will become a public company and is expected to be listed on the NYSE under the new ticker symbol (ABVE). Above Food is a differentiated, vertically integrated, plant-based ingredient and food company dedicated to regenerative agriculture and sustainable food technologies that create a healthier world. The proposed transaction reflects a pro forma enterprise valuation of approximately $319M. Consideration will be 100% in the form of rollover shares and the proposed transaction is expected to provide approximately $44M of gross proceeds to fund future facility development and working capital. Above Food has already received $9M of investments from several high-profile strategic and financial investors including Lexington Capital and Grupo Vida. These investors' financial commitment to Above Food is expected to generate significant commercial and operational synergies for Above Food in the years to come. The transaction has been unanimously approved by the board of directors of Above Food and Bite, and closing, expected for the second half of 2023, is subject to satisfaction of customary closing conditions, including the approval of Bite shareholders. Existing Above Food shareholders, including management will roll over 100% of their equity into the combined company, and will remain majority shareholders with an approximate 70% ownership following the closing of the business combination. Following the closing of the transaction, Above Food's management team will continue to lead the company. Key executives include Lionel Kambeitz, chair, president, and CEO; Jason Zhao, CFO; Martin Williams, president and chief innovation officer of Above Food Brands, Inc; Tyler West, CEO and President, Purely Canada Foods and Donato Sferra, executive VP and chief corporate development officer. At closing, Above Food's board of directors will be comprised of seven members, three of whom will be co-nominated by Bite and certain strategic investors, and four of whom will be nominated by Above Food.

07:39 EDT Marker Therapeutics announces non-dilutive agreement with CellReady - Marker Therapeutics announced that it has entered into a comprehensive agreement with CellReady, a newly formed Contract Development and Manufacturing Organization, CDMO. Under the terms of the non-dilutive agreement, CellReady will purchase certain cell manufacturing assets from Marker for approximately $19M in cash and reduce Marker's overhead by about $11M annually by employing Marker's manufacturing, development, quality, and regulatory affairs personnel, and assuming the leases for Marker's Houston-based manufacturing and research and development facilities. The parties anticipate the transaction will close on June 26, 2023. Juan Vera, M.D., formerly Marker's COO and Chief Scientific Officer, has assumed the role of Chief Executive Officer of Marker Therapeutics effective May 1, 2023. Dr. Vera commented, "Marker's management and impartial members of the board worked with John Wilson and CellReady to develop a very creative and non-dilutive plan that provides Marker with the financial runway to pursue its clinical priorities through the end of 2025. At the same time, through CellReady, Marker will maintain full access to its industry-leading operational, quality, development, and regulatory team and facilities whenever it needs them. I look forward to working with the Marker clinical team to advance the development of MT-601 in our ongoing non-Hodgkin's lymphoma trial and eventual pancreatic cancer trial, in addition to MT-401 for our post-transplant AML trail. Additionally, I am spearheading a strategic review process of our clinical programs with the Marker management team as part of our restructuring efforts." In connection with this transaction, Marker's board of directors established a special transactions committee of impartial directors to review the terms of the transaction, as well as other strategic alternatives, and to issue a recommendation to the board of directors. The impartial members of the board of directors unanimously approved entry into the transaction based on the special transactions committee's recommendation.

07:37 EDT Norwegian Cruise Line expects FY23 occupancy averaging 103.5% - The company said, "The Company continued its phased Occupancy ramp-up in the first quarter of 2023 achieving a 15-point sequential improvement to approximately 101.5%, exceeding guidance of approximately 100%. The phased Occupancy ramp-up is expected to be complete in the second quarter at approximately 105%. As planned, this is slightly lower than the second quarter of 2019, reflecting the Company's strategic shift to longer, more immersive itineraries. Full year 2023 Occupancy, which reflects the phased voyage ramp-up, is expected to average 103.5%, consistent with prior guidance. On the heels of a very strong WAVE season, the Company continues to experience strong consumer demand. Cumulative booked position for the remainder of 2023 is ahead of 2019 levels inclusive of the Company's approximately 18% increase in capacity, at continued higher pricing. As of March 31, 2023, the Company's advance ticket sales balance, including the long-term portion, was a record $3.4 billion, approximately 26% higher than the prior quarter and approximately 60% higher than the first quarter of 2019. Onboard revenue generation remains robust, and the Company continues to focus on increasing its pre-sold revenue from guests prior to voyage sailing, as this typically results in higher overall spend throughout the cruise journey. Total revenue per Passenger Cruise Day was up approximately 17.5% as-reported and approximately 18.3% in constant currency in the first quarter of 2023 versus 2019. Looking ahead, full year guidance remains unchanged at Net Per Diem growth in the range of 9.0 to 10.5% and Net Yield growth in the range of 5.0 to 6.5%, both on a constant currency basis and compared to 2019. The Company continues to focus on efforts to maximize revenue opportunities and right size its cost base in order to strengthen the foundation for sustained, profitable growth. Gross Cruise Costs per Capacity Day was approximately $301 in constant currency in the quarter, compared to $323 in the second half of 2022. Adjusted Net Cruise Costs excluding Fuel per Capacity Day in constant currency in the first quarter of 2023 was approximately $161, lower than the second half of 2022 at $187, and improved versus guidance of $165 as cost savings from the ongoing margin enhancement initiative were realized earlier than anticipated. Based on initiatives already identified and implemented, the Company expects this metric to show continued modest sequential improvement throughout 2023."

07:35 EDT Anavex announces issuance of new U.S. patent expanding ANAVEX2-73 - Anavex Life Sciences announced it was granted a new U.S. Patent No. 11,622,955 entitled "SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY," from the United States Patent and Trademark Office, USPTO, expanding Anavex's coverage of treatment methods for ANAVEX(R)2-73, to the treatment of systolic hypertension, or lowering systolic blood pressure. "We are extremely pleased with the expansion of the patent portfolio for ANAVEX(R)2-73 for the indication of hypertension which affects nearly half of adults in the United States, especially since elevated systolic blood pressure is a major health economy problem within our aging society," said Christopher Missling, PhD, President and Chief Executive Officer of Anavex. "This new patent will add to our already robust patent portfolio relating to ANAVEX2-73, and further demonstrate our strong overall commitment to protecting the full range of commercial opportunities of our product portfolio." Anavex's newest patent will be expected to remain in force at least until November 2038, not including any patent term extensions. The new patent expands existing protections for the use of ANAVEX(R)2-73 in treating neurodegenerative disorders to the new use for treating systolic hypertension in addition to existing antihypertension therapy. The market for uncontrolled hypertension is 37 million adults in the U.S. alone.

07:33 EDT SPX Corporation announces agreement to purchase ASPEQ Heating Group - SPX Technologies announced that it has entered into a definitive agreement to purchase ASPEQ Heating Group, a leader in electrical heating solutions, from Industrial Growth Partners, a San Francisco-based private equity firm. ASPEQ will become a part of SPX Technologies' HVAC Heating platform, within its electrical heating business, along with Marley Engineered Products. Under the terms of the agreement, SPX Technologies will purchase ASPEQ and certain tax attributes for approximately $418 million in cash. SPX Technologies intends to finance the acquisition of ASPEQ by drawing on its revolving credit facility and borrowing under its recently announced Incremental Term Loans. The parties anticipate the closing of the transaction in the second quarter of 2023, subject to regulatory clearance under the Hart-Scott-Rodino Act. "We are looking forward to welcoming ASPEQ to the SPX Technologies team," said Gene Lowe, President and CEO of SPX Technologies. "This will be our largest acquisition to date and will significantly expand our portfolio of electrical heating products where we see attractive growth trends, including decarbonization. ASPEQ's strong brands, custom-configured products and components, and diversified end markets are a very complementary fit with our existing HVAC Heating platform. We see multiple opportunities to enhance new product innovation and create efficiencies for customers through shared channels and resources. This is SPX Technologies' 13th acquisition since 2018, and further validates our strategy of building high-quality, market-leading platforms, and creating foundations for further growth in closely adjacent end markets."

07:30 EDT EnCore Energy makes first delivery into uranium sales agreements - enCore Energy has made its first delivery into one of the company's four previously announced contracted uranium sales agreements. This delivery of 200,000 pounds U3O8 represents the first portion of the annual deliveries into the 5-year agreement which covers 2 million pounds U3O8 of uranium with significant delivery flexibility for market related pricing. The company acquired uranium under favorable pricing terms in 2022 from a third party and delivered it into this agreement using current spot market pricing indicators to establish the sales price.

07:18 EDT Emerita Resources reports additional assay results from La Romanera Deposit - Emerita Resources announces additional assay results from 21 holes from the ongoing delineation drilling program at La Romanera Deposit, part of Emerita's wholly owned Iberian Belt West Project. These results will be included in the upcoming maiden NI 43-101 compliant mineral resource estimate. Wardell Armstrong International has been engaged to complete the mineral resource estimation of the IBW project and is progressing for completion expected middle of May. IBW hosts three previously identified massive sulphide deposits: La Infanta, La Romanera and El Cura. All deposits are open for expansion along strike and at depth.

07:17 EDT Galera Therapeutics expands commercial leadership team - Galera Therapeutics (GRTX) announced the appointment of accomplished pharmaceutical sales, market access, and commercial operations executives to Galera's senior commercial leadership team, effective immediately. Under the direction of Mark Bachleda, Pharm.D., MBA, Galera's Chief Commercial Officer, the team will be responsible for building out the Company's commercial operations, strategy development, and execution in preparation for the potential U.S. commercial launch of avasopasem in 2023. The Company's appointments include: Patrick Campbell as Vice President of Sales & Account Management; Elizabeth Turner as Vice President of Market Access; Henning Thorsen as Vice President of Commercial Operations. The new senior leaders join Lorraine Walker, Pharm.D., Galera's Vice President of Marketing. Turner joins Galera from Anton Health. Campbell joins Galera from Amgen (AMGN) where he recently served as Executive National Sales Director for Amgen's oncology solid tumor portfolio. Thorsen joins Galera from Better Therapeutics (BTTX) where he served as Head of Commercial Operations.

07:14 EDT Natural Gas Services announces cooperation agreement with Mill Road Capital - Natural Gas Services Group announced that it has entered into a cooperation agreement with affiliated entities of Mill Road Capital, which currently owns approximately 7.3% of the Company's outstanding common shares. Under the agreement, the Company appointed Justin Jacobs and Donald Tringali to its Board of Directors and agreed to include Messrs. Jacobs and Tringali as part of the Company's slate of nominees for election to the Board at the 2023 annual meeting of shareholders, which is scheduled to be held on June 15, 2023. Stephen Taylor, interim CEO and President, will be nominated by the Company to continue his service on the Board. The Company also announces today that Leslie Beyer has informed the Board of her decision to resign. With the appointment of Messrs. Jacobs and Tringali, the Board has as of today filled the two existing vacancies. "The Company is committed to shareholder engagement as well as longer-term opportunities to enhance shareholder value and we look forward to Messrs. Jacobs and Tringali becoming integral members of our Board," said Stephen Taylor, Interim Chief Executive Officer and President and Chairman of the Board of the Company. "This is an important time for the Company, and we are eager to benefit from the perspectives and experience available from the whole board. We also thank Ms. Beyer for her dedicated service and contributions to the Board since June of 2020."

07:12 EDT Axsome joins MHA, State of New York to raise awareness of mental health in May - Axsome Therapeutics is joining Mental Health America, MHA, and the State of New York to raise awareness of mental health during May is Mental Health Month. In observance of the beginning of May is Mental Health Month, Axsome's new corporate headquarters, One World Trade Center in New York City, will be lit in green, the color for mental health awareness, on May 1, 2023. Axsome is supporting this year's MHA 'look around, look within' campaign in observance of May is Mental Health Month. This campaign aims to help people realize how much our overall health is affected by our environment and that mental health can be improved by making where we live a healthier and safer place.

07:11 EDT Gilat Satellite receives multimillion-dollar order for VSATs to be used in Asia - Gilat Satellite Networks announced that the company received a multimillion-dollar order for VSATs to be used to expand the rollout of an advanced disaster response network in Asia. "Gilat's widely-deployed multi-service satellite communications technology is being used by this national disaster response network to ensure service continuity," said Ron Levin, Chief Commercial Officer at Gilat. "We are proud to empower this nation with very high levels of throughput, quality, and resilience for its advanced network, which is setting a new standard for disaster response."

07:09 EDT Minerva announces U.S. FDA filed NDA for roluperidone - Minerva Neurosciences announced that the U.S. Food and Drug Administration, FDA, filed the Company's New Drug Application, NDA, for roluperidone for the treatment of negative symptoms in patients with schizophrenia on April 27, 2023. The decision to file the NDA follows the Company's request for formal dispute resolution and appeal of FDA's October 2022 refuse to file letter. The issues cited in the refuse-to-file decision included those discussed at the type C meeting in April 2022. In granting the appeal, the FDA deciding official agreed with the Company that the issues cited in the refuse-to-file decision should be considered during FDA's review of the NDA. "We thank the FDA for its thoughtful review and consideration of our materials submitted during the formal dispute resolution process. We look forward to continuing to work with the FDA with the ultimate goal of obtaining approval of roluperidone as the first approved treatment for negative symptoms of schizophrenia for the benefit of patients, their families, caregivers, and physicians," said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva.

07:08 EDT Bristol-Myers announces Reblozyl sBLA accepted for priority review - Bristol Myers announced that the FDA has accepted the supplemental Biologics License Application, or sBLA, and the European Medicines Agency, or EMA, has validated the Type II Variation Application for Reblozyl, a first-in-class treatment option, to expand its current indication to include treatment of anemia without previous use of erythropoiesis-stimulating agents, or ESA-naive, in adult patients with very low- to intermediate-risk myelodysplastic syndromes, or MDS, who may require red blood cell, or RBC, transfusions. In the U.S., the FDA has granted the application Priority Review and assigned a Prescription Drug User Fee Act, or PDUFA, goal date of August 28. Priority Review designation underscores the high unmet need and value that Reblozyl could bring to this patient population. In Europe, the EMA's validation of the application confirms the submission is complete and begins the EMA's centralized review process.

07:07 EDT Enthusiast Gaming appoints Tara Fournier as CPO - Enthusiast Gaming Holdings provided an update on its senior management team. Tara Fournier: Tara has joined as Chief People Officer. Most recently, Tara was the Chief Talent Officer at Tremor International and Global Head of HR for Amobee. Amanda Rubin: Amanda has been promoted to EVP, Brand Solutions, assuming responsibility for all Direct Sales, Programmatic Media and Sponsorships. Amanda has been with Enthusiast Gaming for four years, most recently serving as SVP, Direct Sales. Matt Goodman: Matt has been promoted to EVP, Strategic Partnerships, in addition to his current responsibilities for Customer Success. Matt has been SVP, Customer Success for the past two years, creating break-through tent-pole marketing programs, such as NFL Tuesday Night Gaming. Scotty Tidwell: Scotty has been promoted to EVP, Content & Creators, reflecting his broad range of responsibilities for creator talent, and the creative and content sides of the business, including Luminosity Gaming and Storied.

07:07 EDT Bitfarms mines 379 new bitcoin in April - Bitfarms provided a Bitcoin production and mining operations update for April 2023. In addition, earlier Bitfarms announced it had regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2). April 2023 Select Operating Highlights: 5.0 EH/s online as of April 27, 2023, up 52% from April 30, 2022, and up 4% compared to March 31, 2023. 4.7 EH/s average online, compared to 4.6 EH/s in March 2023. 80.6 BTC/average EH/s, down from 91.4 in March 2023. 379 new BTC mined, down 6.4% from April 2022 and down 10.6% from March 2023.12.6 BTC mined daily on average, equivalent to about $369,180 per day and approximately $11.1 million for the month, based on a BTC price of $29,300 on April 30, 2023. In Rio Cuarto, Argentina: Private power producer became fully permitted to provide up to 100 MW, enabling Bitfarms to commence purchasing low-cost power under Bitfarms' purchase agreement, Finished testing of the substation that is now online and capable of delivering 120 MW, Increased active capacity over 100% to 18 MW by energizing 2,100 additional miners, Ended underclocking of existing miners in line with improved economics, and Purchased over 6,200 new Bitmain and MicroBT miners to fill out an additional 22 MW in the first warehouse. Added new hardware diagnostics tool that automates hardware diagnostics and improves hardware repair times. Deployed real-time energy tracking across all sites, allowing for individual machine optimization. Entered into agreements to acquire 22 MW of hydro power capacity and to lease a site in Baie-Comeau, Quebec, subject to customary closing conditions.

07:06 EDT TFF Pharmaceuticals receives additional funding from Leidos - TFF Pharmaceuticals (TFFP) announced that Leidos (LDOS) has awarded the Company additional funding under the DARPA Personalized Protective Biosystems program to develop next-generation countermeasures for military and healthcare personnel. "We are pleased with the continued advancement of this program and our relationship with Leidos," said Harlan Weisman, M.D., Chief Executive Officer of TFF Pharmaceuticals. "There is an unmet need to develop next-generation countermeasures to adequately protect our military and civilian populations. Our technology not only allows for delivery of various countermeasures to neutralize biochemical threats directly at the site of entry, but is also needle-free and temperature independent, making these countermeasures easily deployed and administered with ease for future biochemical threat preparedness and biodefense. We believe our Thin Film Freezing platform has extraordinary potential to improve upon numerous applications, including the development of the next generation of chemical and biological protective technologies that can significantly improve the level of protection for our military and front-line personnel."

07:05 EDT Immix says Bristol-Myers exercises option, enters license for TCR-T candidate - Immatics (IMMX) announced that Bristol Myers Squibb (BMY) has exercised its option and entered into an exclusive worldwide license for the first T cell receptor engineered T cell therapy candidate from their ongoing collaboration. Under the terms of the 2019 multi-target strategic collaboration agreement, which was expanded in 2022, Immatics is developing and validating four TCR-T targets and product candidates through the lead TCR candidate stage. Bristol Myers Squibb can exercise opt-in rights and assume sole responsibility for further worldwide development, manufacturing, and commercialization of the TCR-T cell therapies. This first opt-in is for a novel TCR-T product candidate against a target relevant in multiple solid tumor indications. Immatics to receive an option exercise fee of $15 million. The TCR-T programs developed within the collaboration are directed against solid tumor targets discovered by Immatics using its proprietary XPRESIDENT technology combined with its XCEPTOR TCR discovery and engineering platform to identify specific TCRs against these targets. For each program, Immatics is eligible for up to $505 million in option exercise fee, regulatory and commercial milestone payments, as well as additional tiered royalties on net sales of the licensed product.

07:04 EDT Cabaletta Bio receives FDA Fast Track Designation for CABA-201 - Cabaletta Bio announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track Designation for CABA-201, a 4-1BB-containing fully human CD19-CAR T cell investigational therapy, designed to deplete CD19-positive B cells and improve disease activity in patients with systemic lupus erythematosus and lupus nephritis. "Despite advances over the last few decades, treatment options for SLE remain inadequate. There are currently no curative options available that achieve durable disease remission. Existing therapies typically result in general immunosuppression, require chronic administration, and are often administered in conjunction with steroids and other immunosuppressive medications to reduce disease burden, which can leave patients with continued disease activity, treatment-associated side effects, and impaired quality of life," said David J. Chang, M.D., Chief Medical Officer of Cabaletta. "We believe the FDA's decision to grant Fast Track Designation for CABA-201 underscores the unmet need for a treatment that has the potential to provide deep and durable responses for people living with lupus and potentially other autoimmune diseases where B cells contribute to disease. We look forward to initiating the Phase 1/2 trial for CABA-201 and further evaluating its therapeutic potential for patients in need."

07:02 EDT Enbridge to acquire Aitken Creek Natural Gas Storage for $400M. - Enbridge has, through a wholly-owned subsidiary, entered into a definitive agreement with FortisBC Holdings to acquire its interest in FortisBC Midstream, which holds a 93.8% interest in Aitken Creek Gas Storage facility and a 100% interest in Aitken Creek North Gas Storage facility - collectively, Aitken Creek Storage - for $400M, subject to customary closing adjustments. Aitken Creek Storage is an underground reservoir located 120 kilometers northeast of Fort St. John, B.C., and is the largest and only underground natural gas storage facility in B.C., totaling 77 billion cubic feet of working gas capacity. The transaction is expected to close later in 2023, subject to receipt of customary regulatory approvals and closing conditions.

06:59 EDT NovaBay fulfills $1M order for NeutroPhase cleanser for Chinese company - NovaBay announced that China Pioneer Pharma, a Chinese importer and marketer of branded pharmaceuticals and medical devices, has placed a $1M order for NovaBay's NeutroPhase Skin and Wound Cleanser. NovaBay has fulfilled this order and expects to recognize this revenue in Q2.

06:56 EDT Global Payments CEO Jeff Sloan to step down, Cameron Bready to succeed - Global Payments announced that Jeffrey Sloan is stepping down as CEO and a member of the Board, effective June 1. Sloan will be succeeded by Cameron Bready, currently President and COO of Global Payments, as the company's President and CEO. Bready will also join the company's Board at that time. Bready has served as President and COO of Global Payments since 2019. In this role, he has overseen the company's worldwide merchant solutions businesses, global operations, risk management, product and real estate. Since joining Global Payments as Senior Executive Vice President and CFO in 2014, Bready has been integral to spearheading growth and results across the business.

06:54 EDT Global Payments CEO says Q1 best in four years - "We are pleased to have delivered our best first quarter in four years, exceeding our expectations to start 2023," said Jeff Sloan, CEO. "Both of our key businesses posted exceptional results. Our merchant business proved highly resilient as we saw accelerated growth across a number of worldwide markets and ongoing stability despite incremental macroeconomic distractions. And our core issuer business improved 340 basis points sequentially and delivered its highest rate of year-over-year growth in more than five years. This performance reflects the wisdom of our long term strategies and our consistent focus on execution. We accomplished these results while turning the page on the strategic initiatives we have been executing over the last 12 plus months. First, we are delighted to have closed our acquisition of EVO Payments in late March, and we are off to a strong start with our integration activities. Second, we are pleased to announce the successful closing of the sale of our Netspend consumer business in late April. Third, we completed the divestiture of the Gaming Solutions business immediately following the end of the first quarter. These transactions serve to better align our businesses with our strategy, simplify our portfolio, sharpen our focus on core corporate clients and provide us with enhanced confidence in our growth and margin targets. We are delighted to raise our outlook for the full year following the outstanding financial and operating performance we produced in the first quarter."

06:50 EDT Eli Lilly announces secondary analysis from lebrikizumab study - New secondary analysis from Eli Lilly Phase 3 clinical development program showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body. An additional secondary analysis further demonstrated lebrikizumab's stable and long-lasting results at one year of treatment in patients with moderate-to-severe atopic dermatitis, or AD, commonly called eczema. These results from the ADvocate and ADhere studies were presented at the 5th annual Revolutionizing Atopic Dermatitis, or RAD, Congress. Lebrikizumab is an investigational high-affinity and potent IL-13 inhibitor being studied in adult and adolescent patients 12 years of age and older with moderate-to-severe AD. Lilly and partner Almirall S.A. expect regulatory decisions in the U.S. and European Union later this year. A post-hoc analysis based on data from the 16-week induction periods of the ADvocate 1 and ADvocate 2 studies and the ADhere study showed 58% to 73% of adult and adolescent patients treated with lebrikizumab experienced improvement or clearance of face or hand dermatitis. Improved or cleared skin was seen with and without the use of topical corticosteroids, or TCS. Eighty percent of patients treated with lebrikizumab in ADvocate 1 and ADvocate 2 maintained EASI-75 response at one year after achieving EASI-75 response with lebrikizumab treatment at 16 weeks, with more than 70 percent maintaining EASI-75 response with no or minimal fluctuations across 10 study visits through one year of treatment. Patients treated with the four-week dosing regimen saw similar improvements compared to patients treated with two-week dosing. This post-hoc analysis is based on individual patient trajectory data from two double-blind, placebo-controlled, monotherapy Phase 3 studies of lebrikizumab in adult and adolescent patients with moderate-to-severe AD. No safety analysis was conducted as part of these post-hoc analyses. Safety among patients in ADvocate 1 and ADvocate 2 at one year was consistent with the induction phase of the trials and other lebrikizumab studies in AD, including ADhere. The proportion of lebrikizumab-treated patients who reported an adverse event, or AE, in ADvocate 1 and ADvocate 2 at one year was 58 percent and 68 percent, respectively. Most AEs across the two studies were mild or moderate in severity, nonserious, and did not lead to treatment discontinuation. The most commonly reported AEs were conjunctivitis, common cold and headache. Additional lebrikizumab data will be shared at RAD including results from an integrated safety analysis from eight trials and response in patients previously treated with dupilumab. Data from the Phase 3 ADvocate 1 and ADvocate 2 studies were recently published in the New England Journal of Medicine, or NEJM, and British Journal of Dermatology, or BJD. In addition, JAMA Dermatology published detailed results from the ADhere TCS combination study of lebrikizumab. Lilly has exclusive rights for development and commercialization of lebrikizumab in the U.S. and the rest of the world outside Europe. Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe.

06:41 EDT Park Hotels & Resorts sees Q2 RevPAR growth 7%-11% y/y

06:37 EDT Park Hotels & Resorts CEOI says 'we exceeded expectations' in Q1 - Thomas Baltimore, Jr., Chairman and CEO, stated, "I am pleased to report another very strong quarter where we exceeded expectations and continued to execute against our strategic priorities. Results were driven by on-going improvements at our urban hotels and sustained strength in our resort markets, while an acceleration in group trends helped to drive healthy margin gains during the quarter. As we anticipated, the rebound at our urban hotels was very robust, with RevPAR for the first quarter of 2023 increasing 81% compared to the first quarter of 2022, while RevPAR at our resort hotels increased 13% compared to the first quarter of 2022. Hawaii continues to outperform despite the absence of notable Japanese demand with RevPAR up 26% during the first quarter of 2023 over the first quarter of 2022. Group performance was also better than expected and is forecasted to be one of the main drivers of Park's outsized growth this year, with quarterly group revenues exceeding our forecast by 15%, while 2023 Group Revenue Pace now stands at 82% of 2019. Additionally, we made significant progress during the quarter on the capital allocation front, repurchasing approximately 8.8 million shares of our common stock at a significant discount to Net Asset Value and increasing our recurring quarterly dividend to $0.15 per share. Finally, we remain laser-focused on continuing to reshape and improve our portfolio through value-enhancing ROI projects with more than $300 million of projects currently underway. Despite increased macroeconomic uncertainty, Park remains very well-positioned to execute on our strategic initiatives and create long-term value for shareholders with approximately $1.8 billion of liquidity."

06:09 EDT Westport appoints Fabien Redon as Chief Technology Officer - Westport appointed Fabien Redon as the company's Chief Technology Officer and Executive VP of Product Development. Redon will join Westport having served for five years as executive vice president and CTO for Achates Power. Prior to his most recent role, Redon held several other executive positions with Achates Power leading the company's Technology, and Performance and Emissions Development activities. He has also held senior roles with leading global companies including General Motors and Detroit Diesel. Redon assumes this role effective May 1.

06:07 EDT Wah Fu Education and Nanjing Agricultural University launch online evaluation - Wah Fu Education entered into an agreement with Nanjing Agricultural University's School of Continuing Education to co-operate on the launch of a "comprehensive evaluation system of online education" for self-taught examinations. In the future, the two parties will work together to reshape the education for self-taught examinations. Wah Fu will be responsible for the development, technical operations and maintenance of the online learning platform involved in the program of "comprehensive evaluation of online education". Wah Fu will also assist Nanjing Agricultural University in completing the technological development of distance education and learning support. Wah Fu's learning assessment system can record and certify the assessment outcomes for self-taught examination in higher education.

06:04 EDT RadNet receives FDA clearance for its release of Quantib Prostate 3.0 Software - RadNet announced that it has received FDA clearance for the third-generation release of its Quantib Prostate 3.0 MRI artificial intelligence software, further enhancing the offering with new and updated tools. Quantib Prostate software for MRI reading support was first introduced in the US, followed by a class IIb CE marking in Europe in 2021. The FDA 510k special clearance introduces a major upgrade to the latest Quantib Prostate 2.1 release. The upcoming release of the product will include an improved prostate and sub-region segmentation algorithm, automated drawing of the lesions on the PI-RADS sector map, and other functionalities that will enhance the user experience.

06:04 EDT Turtle Beach has engaged with Immersion to avoid proxy contest - Turtle Beach (HEAR) has engaged in good faith with Immersion (IMMR) since their initial outreach in an attempt to reach an agreement that would avoid a proxy contest. To that end, Turtle Beach offered to enter into a short term NDA with Immersion on April 30, in an attempt to share the announcements. Furthermore, on April 30, the board sent a letter to Immersion, indicating why after extensive due diligence it is unable to accept the terms that Immersion most recently proposed, along with a further counter-proposal, which it believes is in the best interest of all Turtle Beach shareholders. The Turtle Beach board remains open to finding a mutually acceptable agreement that is in the best interests of all shareholders. The date of the company's 2023 annual stockholder meeting has not yet been announced. Turtle Beach shareholders are not required to take any action at this time.

06:02 EDT Turtle Beach elects Terry Jimenez as non-executive chairman - In connection with Stark's decision to step down as chairman, the board has elected to separate the roles of chairman of the board and CEO going forward and has unanimously elected Terry Jimenez as non-executive chairman of the board. Jimenez joined the board in October 2022 as an independent director nominated by one of the company's largest shareholders and brings meaningful public company expertise and business and financial experience to the boardroom. Jimenez most recently served as CEO, president and board member at Tribune Publishing Company, a media company, and previously served as its CFO. In addition, both Stark and William Keitel, lead independent director, have informed the board that they will not stand for re-election at the company's 2023 annual meeting, and Keitel will step down from his role as lead independent director, effective immediately, a role the board does not intend to fill in light of the appointment of a non-executive chairman. The board intends to appoint a shareholder representative in Keitel's place, to be nominated for election at the 2023 annual meeting.

05:34 EDT Nio delivers 6,658 vehicles in April - Nio announced its April delivery results. Nio delivered 6,658 vehicles in April, representing an increase of 31.2% year-over-year. The deliveries consisted of 1,713 premium smart electric SUVs, and 4,945 premium smart electric sedans. Cumulative deliveries of Nio vehicles reached 327,255 as of April 30. In April, the majority of deliveries were attributable to ET5 and ES7, while Nio has been upgrading its product offerings from Nio Technology 1.0 to Nio Technology 2.0..In late April, Nio started to steadily ramp up the production and delivery of the EC7, a five-seater smart electric flagship coupe SUV from NT2.0.

05:29 EDT JPMorgan to acquire majority of assets of First Republic Bank - JPMorgan (JPM) announced it has acquired the substantial majority of assets and assumed the deposits and certain other liabilities of First Republic Bank (FRC) from the Federal Deposit Insurance Corporation, or FDIC. In carrying out this transaction, JPMorgan Chase is supporting the U.S. financial system through its significant strength and execution capabilities. As part of the purchase, JPMorgan Chase is assuming all deposits - insured and uninsured. Key transaction elements following the FDIC's competitive bidding process include: Acquisition of the substantial majority of First Republic Bank's assets, including approximately $173B of loans and approximately $30B of securities. Assumption of approximately $92B of deposits, including $30B of large bank deposits, which will be repaid post-close or eliminated in consolidation. FDIC will provide loss share agreements covering acquired single-family residential mortgage loans and commercial loans, as well as $50B of five-year, fixed-rate term financing. JPMorgan Chase is not assuming First Republic's corporate debt or preferred stock. First Republic branches will open on Monday, May 1, as normal, and clients will continue to receive uninterrupted service, including digital and mobile banking capabilities. As a result of this transaction, JPMorgan Chase expects to: Recognize an upfront, one-time, post-tax gain of approximately $2.6B, which does not reflect the approximately $2B dollars of post-tax restructuring costs anticipated over the next 18 months. Remain very well-capitalized with a CET1 ratio consistent with its 1Q 24 target of 13.5% and maintain healthy liquidity buffers The transaction is expected to be modestly EPS accretive and generate more than $500M of incremental net income per year, not including the approximately $2.6B one-time post-tax gain or approximately $2B of post-tax restructuring costs expected over the course of 2023 and 2024. The acquired First Republic businesses will be overseen by JPMorgan Chase's Consumer and Community Banking, or CCB, co-CEOs, Marianne Lake and Jennifer Piepszak.

05:20 EDT Bitfarms regains compliance with Nasdaq - Bitfarms has received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550. On December 13, 2022, Nasdaq notified Bitfarms that its common stock no longer complied with the minimum bid price requirement of $1.00 over the previous 30 consecutive trading days as required by the Listing Rules of Nasdaq. Subsequently, by letter dated April 28, Nasdaq determined that for the preceding 13 consecutive trading days, from April 11, through April 27, the closing bid price of Bitfarms' common stock was $1.00 per share or greater, and the company has therefore regained compliance with Listing Rule 5550.

04:28 EDT First Republic put into receivership, JPMorgan assumes all deposits - First Republic Bank (FRC) was closed by the California Department of Financial Protection and Innovation, which appointed the Federal Deposit Insurance Corporation as receiver. To protect depositors, the FDIC is entering into a purchase and assumption agreement with JPMorgan Chase (JPM) to assume all of the deposits and substantially all of the assets of First Republic Bank, the agency said in a statement. JPMorgan submitted a bid for all of First Republic Bank's deposits. As part of the transaction, First Republic Bank's 84 offices in eight states will reopen as branches of JPMorgan Chase Bank today during normal business hours. All depositors of First Republic Bank will become depositors of JPMorgan Chase and will have full access to all of their deposits. As of April 13, First Republic Bank had approximately $229.1B in total assets and $103.9B in total deposits. In addition to assuming all of the deposits, JPMorgan agreed to purchase substantially all of First Republic Bank's assets. The FDIC and JPMorgan are also entering into a loss-share transaction on single family, residential and commercial loans it purchased of the former First Republic Bank. The FDIC as receiver and JPMorgan will share in the losses and potential recoveries on the loans covered by the loss-share agreement. The loss-share transaction is projected to maximize recoveries on the assets by keeping them in the private sector. The FDIC estimates that the cost to the Deposit Insurance Fund will be about $13B. Reference Link